NovaBridge Biosciences (NBP) Payables (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Payables data on file, last reported at $16.8 million in Q4 2025.

• Quarterly Payables rose 123.35% year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.8 million (up 123.35% YoY) and the FY2025 annual result came in at $16.8 million, up 123.35% from the prior year.
• Payables climbed to $16.8 million in Q4 2025 per NBP's latest filing, from $7.5 million in the prior quarter.
• Across five years, Payables topped out at $102.0 million in Q4 2022 and bottomed at $4.3 million in Q2 2023.
• The 5-year median for Payables is $35.3 million (2023), against an average of $46.2 million.
• The widest annual swing landed in 2024, when Payables plunged 86.01%; it then jumped 123.35% in 2025.
• Tracing NBP's Payables over 5 years: stood at $92.8 million in 2021, then climbed by 9.92% to $102.0 million in 2022, then tumbled by 47.21% to $53.8 million in 2023, then sank by 86.01% to $7.5 million in 2024, then jumped by 123.35% to $16.8 million in 2025.
• Per Business Quant, the three latest NBP Payables figures stand at $16.8 million (Q4 2025), $7.5 million (Q4 2024), and $53.8 million (Q4 2023).

Peer Comparison